drugset / Trial / NCT04409834

Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial

NCT04409834

Phase 4 Completed 390 enrolled The TIMI Study Group
RandomizedParallel-groupOpen-labelPrevention

Summary

The researchers wanted to learn how to help sick patients who are in the hospital because of COVID-19. They are trying to find out the best way that is safe to stop blood clots that could be dangerous from forming in patients with COVID-19. This research study happened at 34 hospitals. All patients in the study took medicines that help prevent blood clots. These medicines are called blood thinners or anticoagulants. Patients got different amounts of blood thinners to see what works better and is safer. Researchers randomly chose some patients to get more and some to get less. The researchers also wanted to know if another medicine called clopidogrel can safely help stop blood clots from forming. This kind of medicine helps keep parts of the blood, called platelets, from sticking together. In some patients who did not have other reasons to take a platelet-blocker the researchers randomly chose the patient to take clopidogrel or not. This type of medicine is also called an antiplatelet.

Timeline

Start
2020-08-05
Primary completion
2022-03-10
Completion
2022-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject Enoxaparin sodium Other / unclassified 1 mg/kg Subcutaneous
Subject Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject Heparin Other / unclassified 5000 iu Intravenous